Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 364

1.

Smartphone-Based Meditation for Myeloproliferative Neoplasm Patients: Feasibility Study to Inform Future Trials.

Huberty J, Eckert R, Larkey L, Kurka J, Rodríguez De Jesús SA, Yoo W, Mesa R.

JMIR Form Res. 2019 Apr 29;3(2):e12662. doi: 10.2196/12662.

2.

Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44].

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M.

Leuk Res. 2019 Jun;81:105. doi: 10.1016/j.leukres.2019.04.006. Epub 2019 Apr 24. No abstract available.

PMID:
31029462
3.

Development of a symptom assessment in patients with myelofibrosis: qualitative study findings.

Mesa RA, Su Y, Woolfson A, Prchal JT, Turnbull K, Jabbour E, Scherber R, Shields AL, Krohe M, Ojo F, Pompilus F, Cappelleri JC, Harrison C.

Health Qual Life Outcomes. 2019 Apr 11;17(1):61. doi: 10.1186/s12955-019-1121-1.

4.

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M.

Leuk Res. 2019 Apr;79:38-44. doi: 10.1016/j.leukres.2019.02.012. Epub 2019 Feb 28. Erratum in: Leuk Res. 2019 Apr 24;:.

PMID:
30849661
5.

Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey.

Yu J, Paranagama D, Geyer HL, Parasuraman S, Mesa R.

Ann Hematol. 2019 May;98(5):1119-1125. doi: 10.1007/s00277-019-03610-4. Epub 2019 Jan 29.

6.

Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.

Mazza GL, Kunze KL, Langlais BT, Kosiorek HE, DeWees TA, Geyer HL, Scherber RM, Mesa RA, Dueck AC.

Leuk Lymphoma. 2019 Jan 17:1-7. doi: 10.1080/10428194.2018.1548705. [Epub ahead of print]

PMID:
30652523
7.

Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK.

Biol Blood Marrow Transplant. 2019 Jan 6. pii: S1083-8791(19)30005-9. doi: 10.1016/j.bbmt.2019.01.002. [Epub ahead of print]

PMID:
30625392
8.

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.

Rampal RK, Mascarenhas JO, Kosiorek HE, Price L, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Menghrajani K, Najfeld V, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Goldberg JD, Hoffman R.

Blood Adv. 2018 Dec 26;2(24):3572-3580. doi: 10.1182/bloodadvances.2018019661.

9.

Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF.

Scherber RM, Mesa RA.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):118-126. doi: 10.1182/asheducation-2018.1.118. Review.

PMID:
30504300
10.
11.

Perceptions of Myeloproliferative Neoplasm Patients Participating in an Online Yoga Intervention: A Qualitative Study.

Huberty J, Eckert R, Larkey L, Gowin K, Mitchell J, Mesa R.

Integr Cancer Ther. 2018 Dec;17(4):1150-1162. doi: 10.1177/1534735418808595. Epub 2018 Oct 23.

12.

Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis.

Palmer J, Scherber R, Girardo M, Geyer H, Kosiorek H, Dueck A, Jain T, Mesa R.

Biol Blood Marrow Transplant. 2019 Feb;25(2):398-402. doi: 10.1016/j.bbmt.2018.09.033. Epub 2018 Oct 4.

PMID:
30292010
13.

Refining the management of polycythemia vera.

Mesa RA.

Clin Adv Hematol Oncol. 2018 Sep;16(9):587-589. Review. No abstract available.

PMID:
30256773
14.

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States.

Grunwald MR, Stein BL, Boccia RV, Oh ST, Paranagama D, Parasuraman S, Colucci P, Mesa R.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):788-795.e2. doi: 10.1016/j.clml.2018.08.009. Epub 2018 Aug 29.

15.

Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis.

Menghrajani K, Boonstra PS, Mercer JA, Perkins C, Gowin KL, Weber AA, Mesa R, Gotlib JR, Wang L, Singer JW, Talpaz M.

Leuk Lymphoma. 2019 Apr;60(4):1036-1042. doi: 10.1080/10428194.2018.1509315. Epub 2018 Sep 20.

PMID:
30234400
16.

Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.

Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L, Salama ME, Weinberg RS, Rampal R, Farnoud N, Dueck AC, Mascarenhas JO, Hoffman R.

Biol Blood Marrow Transplant. 2019 Feb;25(2):256-264. doi: 10.1016/j.bbmt.2018.09.001. Epub 2018 Sep 8.

PMID:
30205231
17.

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.

Mesa R, Boccia RV, Grunwald MR, Oh ST, Colucci P, Paranagama D, Parasuraman S, Stein BL.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):590-596. doi: 10.1016/j.clml.2018.05.020. Epub 2018 May 28.

18.

Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.

Mughal TI, Lion T, Abdel-Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R.

Hematol Oncol. 2018 Dec;36(5):740-748. doi: 10.1002/hon.2537. Epub 2018 Aug 3. Review.

PMID:
30074634
19.

Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life?

Langlais BT, Geyer H, Scherber R, Mesa RA, Dueck AC.

Leuk Lymphoma. 2019 Feb;60(2):402-408. doi: 10.1080/10428194.2018.1480768. Epub 2018 Jul 22.

PMID:
30033837
20.

Continuous Transitional Focus (CTF): A New Concept in Ophthalmic Surgery.

Mesa RR, Monteiro T.

Ophthalmol Ther. 2018 Dec;7(2):223-231. doi: 10.1007/s40123-018-0134-x. Epub 2018 Jun 18. Review.

Supplemental Content

Loading ...
Support Center